T2 Biosystems Announces Proposed Public Offering of Common Stock

T2 Biosystems (Nasdaq:TTOO), an emerging leader in the development and commercialization of innovative diagnostic products for critical unmet needs in healthcare, today announced that it is commencing an underwritten registered public offering of 5,650,000 shares of its common stock.

As quoted in the press release:

T2 Biosystems also intends to grant the underwriters a 30-day option to purchase up to an additional 847,500 shares of its common stock.  All of the shares are being offered by T2 Biosystems. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Leerink Partners LLC is acting as joint book-running manager for the offering.  Canaccord Genuity LLC is acting as passive book-running manager.  Janney Montgomery Scott LLC, JonesTrading Services LLC and WBB Securities, LLC are acting as co-managers for the offering.

Click here to read the full press release.